Clinical implications of the molecular biology of erythropoietic protoporphyria

Journal of the European Academy of Dermatology and Venereology

Volumn 11, Issue 3, 1998, Pages 207-213

  Todd, David J ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

Author keywords

Erythropoietic protoporphyria; Ferrochelatase; Gene therapy; Inheritance; Mutations

Indexed keywords

FERROCHELATASE;

CHROMOSOME 18; CLINICAL ARTICLE; ERYTHROPOIETIC PROTOPORPHYRIA; GENE MAPPING; GENE MUTATION; GENE THERAPY; HUMAN; LIVER FAILURE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0032420325     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0926-9959(98)00080-4     Document Type: Article

References (83)

1. Kappas A, Sassa S, Galbraith RA, Nordmann Y. The Porphyrias. In: Scriver ER, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 1995:2139-2141.
2. Went LN, Klasen EC. Genetic aspects of erythropoietic protoporphyria. Ann Hum Genet 1984;48:105-117.
3. Todd DJ. Erythropoietic protoporphyria. Br J Dermatol 1994;131:751-766.
4. Todd DJ. A clinical and genetic study of erythropoietic protoporphyria in Northern Ireland (MD thesis). Queen's University, Belfast, 1993:45-46.
5. Doss MO, Frank M. Hepatobiliary implications and complications in protoporphyria, a 20 year study. Clin Biochem 1989;22:223-229.
6. Mathews-Roth MM. The consequences of not diagnosing erythropoietic protoporphyria. Arch Dermatol 1980;116:407.
7. Sarkany RPE, Norris PG. Hepatic complications of erythropoietic protoporphyria. Br J Dermatol 1994;130:258-259.
8. DeLeo VA, Poh-Fitzpatrick M, Mathews-Roth M, Harber LC. Erythropoietic protoporphyria: 10 years experience. Am J Med 1976;60:8-22.
9. Todd DJ, Nevin NC, Burrows D. Prevalence of gallstones in patients with erythropoietic protoporphyria in Northern Ireland. J Eur Acad Dermatol Venereol 1991;1:109-112.
10. Todd DJ. Gallstones in children. Am J Dis Child 1991;145:971-972.
11. Labbe-Bois R. The ferrochelatase from Saccharomyces cerevisiae. J Biol Chem 1990;265:7278-7283.
12. Taketani S, Nakahashi Y, Osumi T, Tokunaga R. Molecular cloning, sequencing, and expression of mouse ferrochelatase. J Biol Chem 1990;265:19377-19380.
13. Nakahashi Y, Taketani S, Okuda M, Inoue K, Tokunaga R. Molecular cloning and sequence analysis of cDNA encoding human ferrochelatase. Biochem Biophys Res Commun 1990;173:748-755.
14. Whitcombe DM, Carter NP, Albertson DG, Smith SJ, Rhodes DA, Cox TM. Assignment of the human ferrochelatase gene (FECH) and a locus for protoporphyria to chromosome 18q22. Genomics 1991;11:1152-1154.
15. Taketani S, Inazawa J, Nakahashi Y, Abe T, Tokunaga R. Structure of the human ferrochelatase gene: exon/intron gene organization and location of the gene to chromosome 18. Eur J Biochem 1992;205:217-222.
16. Brenner DA, Didier JM, Frasier F, Christensen SR, Evans GA, Dailey HA. A molecular defect in human protoporphyria. Am J Hum Genet 1992;50:1203-1210.
17. Whitcome DM, Albertson DG, Cox TM. Molecular analysis of functional and nonfunctional genes for human ferrochelatase: isolation and characterization of a FECH pseudogene and its sublocalization on chromosome 3. Genomics 1994;20:482-486.
18. Tugores A, Magness ST, Brenner DA. A single promoter directs both housekeeping and erythroid preferential expression of the human ferrochelatase gene. J Biol Chem 1994; 269:30789-30797.
19. Furukawa T, Tokunaga R, Taketani S. Regulation of the ferrochelatase gene expression during differentiation of mouse erythroleukemia cells. Biochem Mol Biol Int 1997;41:1161-1170.
20. Chan RYY, Schulman HM, Ponka P. The expression of ferrochelatase mRNA in erythroid and non erythroid cells. Biochem J 1993;292:343-349.
21. Lamoril J, Boulechfar S, Verneuil H, Grandchamp B, Nordmann Y, Deybach J-C. Human erythropoietic protoporphyria: two point mutations in the ferrochelatase gene. Biochem Biophys Res Commun 1991;181:594-599.
22. Nakahashi Y, Fujita H, Taketani S, Ishida N, Kappas A, Sassa S. The molecular defect of ferrochelatase in a patient with erythropoietic protoporphyria. Proc Natl Acad Sci USA 1992;89:281-285.
23. Nakahashi Y, Miyazaki H, Kadota Y, Naitoh Y, Inoue K, Yamamoto M, Hayashi N, Taketani S. Molecular defect in human erythropoietic protoporphyria with fatal liver failure. Hum Genet 1993;91:303-306.
24. Nakahashi Y, Miyazaki H, Kadota Y, Naitoh Y, Inoue K, Yamamoto M, Hayashi N, Taketani S. Human erythropoietic protoporphyria: identification of a mutation at the splice donor site of intron 7 causing exon 7 skipping of the ferrochelatase gene. Hum Mol Genet 1993;2:1069-1070.
25. Wang X, Poh-Fitzpatrick M, Carriere D, Ostasiewicz L, Chen T, Taketani S, Piomelli S. A novel mutation in erythropoietic protoporphyria: an aberrant ferrochelatase mRNA caused by exon skipping during RNA splicing. Biochim Biophys Acta 1993;1181:198-200.
26. Todd DJ, Hughes AE, Ennis KT, Ward AJ, Burrows D, Nevin NC. Identification of a single base pair deletion (40 del G) in exon 1 of the ferrochelatase gene in patients with erythropoietic protoporphyria. Hum Mol Genet 1993;2:1495-1496.
27. Wang X, Poh-Fitzpatrick M, Taketani S, Chen T, Piomelli S. Screening for ferrochelatase mutations: molecular heterogeneity of erythropoietic protoporphyria. Biochim Biophys Acta 1994;1225:187-190.
28. Sarkany RPE, Whitcombe DM, Cox TM. Molecular characterization of a ferrochelatase gene defect causing anomalous RNA splicing in erythropoietic protoporphyria. J Invest Dermatol 1994;102:481-484.
29. Sarkany RPE, Alexander GJMA, Cox TM. Recessive inheritance of erythropoietic protoporphyria with liver failure. Lancet 1994;343:1393-1396.
30. Schneider-Yin X, Schäfer BW, Möhr P, Burg G, Minder Ei. Molecular defects in erythropoietic protoporphyria with terminal liver failure. Hum Genet 1994;93:711-713.
31. Wang X, Poh-Fitzpatrick M, Piomelli S. A novel splicing mutation in the ferrochelatase gene responsible for erythropoietic protoporphyria. Biochim Biophys Acta 1994;1227: 25-27.
32. Magness ST, Tugores A, Christensen SR, Wagner-Mcpherson C, Evans GA, Naylor EW, Brenner DA. Deletion of the ferrochelatase gene in a patient with protoporphyria. Hum Mol Genet 1994;3:1695-1697.
33. Schneider-Yin X, Schäfer BW, Tönz O, Minder EI. Human ferrochelatase: a novel mutation in patients with erythropoietic protoporphyria and an isoform caused by alternative splicing. Hum Genet 1995;95:391-396.
34. Wang X, Poh-Fitzpatrick M, Chen T, Malavade K, Carriero D, Piomelli S. Systematic screening for RNA with skipped exons-splicing mutations of the ferrochelatase gene. Biochim Biophys Acta 1995;1271:358-362.
35. Gouya L, Deybach JCh, Lamoril J, Da Silva V, Beaumont C, Grandchamp B, Nordmann Y. Modulation of the phenotype in dominant erythropoietic protoporphyria by a low expression of the normal ferrochelatase allele. Am J Hum Genet 1996;58:292-299.
36. Henriksson M, Timonen K, Mustajoki P, Pihlaja H, Tenhunen R, Peltonen L, Kauppinen R. Four novel mutations in the ferrochelatase gene among erythropoietic protoporphyria patients. J Invest Dermatol 1996;106:346-350.
37. Imoto S, Tanizawa Y, Sato Y, Kaku K, Oka Y. A novel mutation in the ferrochelatase gene associated with erythropoietic protoporphyria. Br J Haematol 1996;94:191-197.
38. Wang X. Molecular characterization of a novel defect occurring de novo associated with erythropoietic protoporphyria. Biochim Biophys Acta 1996;1316:149-152.
39. Wang X, Piomelli S, Peacocke M, Christiano AM, Poh-Fitzpatrick MB. Erythropoietic protoporphyria: four novel frameshift mutations in the ferrochelatase gene. J Invest Dermatol 1997;109:688-691.
40. Taketani S, Fujita H. The ferrochelatase gene structure and molecular defects associated with erythropoietic protoporphyria. J Bioenerg Biomembr 1995;27:231-238.
41. Wang X, Poh-Fitzpatrick M, Chen T, Malavade K, Sheth S, Piomelli S. A novel molecular defect in erythropoietic protoporphyria: an aberrant ferrochelatase mRNA missing two exons. Blood 1993;82(Suppl l):9a.
42. Rooij FWMde, Baar-Heesakkers Ede, Minderman-Voortman GJ, Wilson JHP. A similarity in mutations of the ferrochelatase gene between Dutch and Japanese patients with erythropoietic protoporphyria. Gastroenterology 1996;110:A1180.
43. Bloomer J, Bruzzone C, Zhu L, Chen F, Scarlett Y, Magness S, Brenner D. Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation. Hepatology 1996;24:199A.
44. Horkay I, Remenyik E, Moore MR, Lanyon GW. A genetic study in erythropoietic protoporphyria. J Eur Acad Dermatol Venereol 1997;9(Suppl 1):S139.
45. Goerz G, Bolsen K, Bunselmeyer S, Schürer NY. Recessive inheritance of erythropoietic protoporphyria with liver failure. Lancet 1994;344:337.
46. Schneider-Yin X, Taketani S, Schäfer B, Minder EI. Recessive inheritance of erythropoietic protoporphyria with liver failure. Lancet 1994;344:337.
47. Sarkany RPE, Alexander GJM, Cox TM. Recessive inheritance of erythropoietic protoporphyria with liver failure. Lancet 1994;344:958-959.
48. Sarkany RPE, Cox TM. Autosomal recessive erythropoietic protoporphyria: a syndrome of severe photosensitivty and liver failure. Q J Med 1995;88:541-549.
49. Tutois S, Montagutelli X, Da Silva V, Jouault H, Rouyer-Fessard P, Leroky-Viard K, Guénet J-L, Nordmann Y, Beuzard Y, Deybach J-C. Erythropoietic protoporphyria in the house mouse: a recessive inherited ferrochelatase deficiency with anemia, photosensitivity and liver disease. J Clin Invest 1991;88:1730-1736.
50. mlpas) in the house mouse. Genomics 1993;16:645-648.
51. Haeger-Aronsen B. Erythropoietic protoporphyria: a new type of inborn error of metabolism. Am J Med 1963;35:450-454.
52. Heager-Aronsen B, Krook G. Erythropoietic protoporphyria: a study of known cases in Sweden. Acta Med Scand 1966;179(Suppl. 445):48-55.
53. Reed WB, Wuepper KD, Epstein JH, Redeker A, Simonson RJ, McKusick VA. Erythropoietic protoporphyria: a clinical and genetic study. J. Am. Med. Assoc. 1970;214:1060-1066.
54. Deybach JC, Da Silva V, Pasquier Y, Nordmann Y. Ferrochelatase in human erythropoietic protoporphyria: the first case of a homozygous form of the enzyme deficiency. In: Nordmann Y, editor. Porphyrins and porphyrias. Paris: Libbey, 1986:163-173.
55. Nunn AVW, Norris P, Hawk JLM, Cox TM. Zinc chelatase in human lymphocytes: detection of the enzymatic defect in erythropoietic protoporphyria. Anal Biochem 1988;174:146-150.
56. Poh-Fitzpatrick MB, Piomelli S, Deybach J-C, Gouya L, Wang X. Erythropoietic protoporphyria: a triallelic inheritance model. J Invest Dermatol 1997;108:598.
57. Todd DJ, Nesbitt GS, Lavery TD, Trimble ER, Burrows D. Erythropoietic protoporphyria. The problem of a suitable screening test. Acta Derm Venereol (Stockh) 1990;70:347-350.
58. Taketani S, Tokunaga R. Rat liver ferrochelatase: purification, properties, and stimulation by fatty acids. J Biol Chem 1981;256:12748-12753.
59. Harbin BM, Dailey HA. Orientation of ferrochelatase in bovine liver mitochondria. Biochemistry 1985;24:366-370.
60. Dailey HA, Sellers VM, Dailey TA. Mammalian ferrochelatase: expression and characterization of normal and two human protoporphyric ferrochelatases. J Biol Chem 1994; 269:390-395.
61. Dailey HA, Finnegan MG, Johnson MK. Human ferrochelatase is an iron-sulfur protein. Biochemistry 1994;33:403-407.
62. Ferreira GC. Ferrochelatase binds the iron-responsive element present in the erythroid 5-aminolevulinate synthase mRNA. Biochem Biophys Res Commun 1995;214:875-878.
63. Houston T, Moore MR, McColl KEL, Fitzsimons EJ. Regulation of haem biosynthesis in normoblastic erythropoiesis: role of 5-aminolaevulinic acid synthase and ferrochelatase. Biochim Biophys Acta 1994;1201:85-93.
64. Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 1997;89:1-25.
65. Todd DJ, Callender ME, Mayne EE, Walsh M, Burrows D. Erythropoietic protoporphyria, transfusion therapy and liver disease. Br J Dermatol 1992;127:534-537.
66. Kohno H, Okuda M, Furukawa T, Tokunaga R, Taketani S. Site-directed mutagenesis of human ferrochelatase: identification of histidine-263 as a binding site for metal ions. Biochim Biophys Acta 1994;1209:95-100.
67. Crouse BR, Sellers VM, Finnegan MG, Dailey HA, Johnson MK. Site-directed mutagenesis and spectroscopic characterization of human ferrochelatase: identification of residues cordinating the [2Fe-2S] cluster. Biochemistry 1996;35: 16222-16229.
68. Mathews-Roth MM. Treatment of erythropoietic protoporphyria with beta-carotene. Photodermatology 1994;1:318-321.
69. Mathews-Roth MM. Erythropoietic protoporphyria. Br J Dermatol 1996;134:977.
70. Johnson JA, Fusaro RM. Broad-spectrum photoprotection: the roles of tinted auto windows, sunscreens and browning agents in the diagnosis and treatment of photosensitivity. Dermatology 1992;185:237-241.
71. Dawe R, Russell S, Ferguson J. Borrowing from museums and industry: two photoprotection devices. Br J Dermatol 1996;135:1016-1017.
72. Mathews-Roth MM, Rosner B, Benfell K, Roberts JE. A double-blind study of cysteine photoprotection in erythropoietic protoporphyria, Photodermatol Photoimmunol Photomed 1994;10:244-248.
73. Roelandt, R. Photo(chemo)therapy and general management of erythropoietic protoporphyria. Dermatology 1995;190: 330-331.
74. Collins P, Ferguson J. Narrow-band UVB (TL-01) phototherapy: an effective preventative treatment for the photodermatoses. Br J Dermatol 1995;132:956-963.
75. Todd DJ, Burrows D. Predictable hazards of erythropoietic protoporphyria. Clin Exp Dermtol 1992;17:141.
76. Meerman L, Verwer R, Sloof MJH, van Hattum J, Beukeveld GJJ, Kleibeuker JH, Haagsma EB. Perioperative measures during liver transplantation for erythropoietic protoporphyria. Transplantation 1994;57:155-158.
77. Mathews-Roth MM, Michel JL, Wise RJ. Amelioration of the metabolic defect in erythropoietic protoporphyria by expression of human ferrochelatase in cultured cells. J Invest Dermatol 1995;104:497-499.
78. Magness ST, Brenner DA. Ferrochelatase cDNA delivered by adenoviral vector corrects biochemical defect in protoporphyric cells. Hum Gene Ther 1995;6:1285-1290.
79. Verneuil Hde, Ged C, Boulechfar S, Moreau-Gaudry F. Porphyrias: animal models and prospects for cellular and gene therapy. J Bioenerg Biomemb 1995;27:239-247.
80. Dunbar CE. Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. Annu Rev Med 1996;47:11-20.
81. Mathews-Roth MM, Wise RJ, Miller BA. Burst-forming units-erythroid from erythropoietic protoporphyria patients fluoresce under 405 nm light. Blood 1996;87:4480-4481.
82. Kohn DB. Gene therapy for haematopoietic and lymphoid disorders. Clin Exp Immunol 1997;107:54-57.
83. Cox TM. Erythropoetic protoporphyria. J Inher Metab Dis 1997;20:258-269.